Bladder Cancer Coverage from Every Angle

Arlene O. Siefker-Radtke, MD, on Combination Therapy With Erdafitinib and Cetrelimab for Metastatic Urothelial Carcinoma

Posted: Wednesday, June 7, 2023

Arlene O. Siefker-Radtke, MD, of The University of Texas MD Anderson Cancer Center, discusses the results from the NORSE trial. In this study, combination therapy with the FGFR inhibitor erdafitinib and the PD-1 inhibitor cetrelimab appeared to be active and well tolerated in cisplatin-ineligible patients who had metastatic urothelial carcinoma and FGFR alterations.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.